SCOPUS 정보 검색 플랫폼

Annals of Internal Medicine

Volumn 161, Issue 5, 2014, Pages 376-377

Treatment of primary sjögren syndrome with rituximab

(3) Faustman, Denise L a Vivino, Frederick B b Carsons, Steven E c

a HARVARD MEDICAL SCHOOL (United States)

b PENN PRESBYTERIAN MEDICAL CENTER (United States)

c WINTHROP UNIVERSITY HOSPITAL (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

CLINICAL ASSESSMENT TOOL; DISEASE ACTIVITY; DISEASE DURATION; DRUG EFFICACY; EUROPEAN LEAGUE AGAINST RHEUMATISM SJOGREN SYNDROME DISEASE ACTIVITY INDEX; FUNCTIONAL ASSESSMENT; HUMAN; HUMORAL IMMUNE DEFICIENCY; LETTER; MOISTURE; OUTCOME ASSESSMENT; PRIMARY SJOEGREN SYNDROME; RANDOMIZED CONTROLLED TRIAL (TOPIC); SALIVATION; SJOEGREN SYNDROME; TISSUE INJURY; VISUAL ANALOG SCALE; FEMALE; MALE; NOTE;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; SJOGREN'S SYNDROME;

EID: 84906980128 PISSN: 00034819 EISSN: 15393704 Source Type: Journal
DOI: 10.7326/L14-5017-3 Document Type: Letter

Times cited : (7)

References (5)

1
- 84894243056
- Treatment of primary Sjögren syndrome with rituximab: A randomized trial
- PMID: 24727841
- Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot JM, Perdriger A, Puéchal X, et al. Treatment of primary Sjögren syndrome with rituximab: a randomized trial. Ann Intern Med. 2014;160:233-42. [PMID: 24727841]
- (2014) Ann Intern Med , vol.160 , pp. 233-242
- Devauchelle-Pensec, V.¹ Mariette, X.² Jousse-Joulin, S.³ Berthelot, J.M.⁴ Perdriger, A.⁵ Puéchal, X.⁶

2
- 84863844268
- Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab
- PMID: 22258489
- Meiners PM, Arends S, Brouwer E, Spijkervet FK, Vissink A, Bootsma H. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab. Ann Rheum Dis. 2012;71:1297-302. [PMID: 22258489] doi:10.1136/annrheumdis-2011-200460
- (2012) Ann Rheum Dis , vol.71 , pp. 1297-1302
- Meiners, P.M.¹ Arends, S.² Brouwer, E.³ Spijkervet, F.K.⁴ Vissink, A.⁵ Bootsma, H.⁶

3
- 77950538947
- Effectiveness of rituximab treatment in primary Sjögren's syndrome: A randomized, double-blind, placebo-controlled trial
- PMID: 20131246
- Meijer JM, Meiners PM, Vissink A, Spijkervet FK, Abdulahad W, Kamminga N, et al. Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62:960-8. [PMID: 20131246] doi:10.1002/art.27314
- (2010) Arthritis Rheum , vol.62 , pp. 960-968
- Meijer, J.M.¹ Meiners, P.M.² Vissink, A.³ Spijkervet, F.K.⁴ Abdulahad, W.⁵ Kamminga, N.⁶

4
- 34248597383
- BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome
- PMID: 17469105
- Pers JO, Devauchelle V, Daridon C, Bendaoud B, Le Berre R, Bordron A, et al. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome. Arthritis Rheum. 2007;56:1464-77. [PMID: 17469105]
- (2007) Arthritis Rheum , vol.56 , Issue.5 , pp. 1464-1477
- Pers, J.O.¹ Devauchelle, V.² Daridon, C.³ Bendaoud, B.⁴ Le Berre, R.⁵ Bordron, A.⁶

5
- 84886552636
- Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: A prospective, multi-center, follow-up study
- PMID: 24286296
- Carubbi F, Cipriani P, Marrelli A, Benedetto P, Ruscitti P, Berardicurti O, et al. Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study. Arthritis Res Ther. 2013;15:R172. [PMID: 24286296] doi:10.1186/ar4359
- (2013) Arthritis Res Ther , vol.15 , pp. R172
- Carubbi, F.¹ Cipriani, P.² Marrelli, A.³ Benedetto, P.⁴ Ruscitti, P.⁵ Berardicurti, O.⁶

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.